Teva's Next Blockbuster? Its Anti-CGRP Antibody Prepares For Phase III In Difficult-To-Treat Migraines
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries confirmed it is to start Phase III studies with TEV-48125, its humanized monoclonal antibody against calcitonin-gene-related peptide (CGRP), but the company was not giving details on timings and indications as it published online Sept. 30 the full Phase IIb clinical trial results with the product in episodic migraine and chronic migraine, in two papers in The Lancet Neurology.
You may also be interested in...
Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data
Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.